Drug intelligence / Profile preview

VE707

Development stage: Preclinical
Lead developer: Vedanta Biosciences
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

VE707 is a preclinical-stage oral live biotherapeutic product (LBP) consisting of a rationally defined consortium of commensal human gut bacteria. Developed by Vedanta Biosciences, it is designed to decolonize the gastrointestinal tract of multidrug-resistant organisms (MDROs), including carbapenem-resistant Enterobacteriaceae (CRE), extended-spectrum beta-lactamase (ESBL) producers, and vancomycin-resistant Enterococci (VRE). The therapy aims to restore a healthy gut microbiota, thereby preventing serious infections and colonization recurrence in high-risk patients without the use of traditional antibiotics. The program has received significant non-dilutive funding from CARB-X and BARDA to support its advancement toward first-in-human clinical trials.

Other names: VE707VE-707VE 707

Beyond the preview

Go deeper on VE707.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VE707.

Explore the full profile